BACKGROUND: Long-standing concern about the effects of type 1 diabetes on cognitive ability has increased with the use of therapies designed to bring glucose levels close to the nondiabetic range and the attendant increased risk of severe hypoglycemia. METHODS: A total of 1144 patients with type 1 diabetes enrolled in the Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study were examined on entry to the DCCT (at mean age 27 years) and a mean of 18 years later with the same comprehensive battery of cognitive tests. Glycated hemoglobin levels were measured and the frequency of severe hypoglycemic events leading to coma or seizures was recorded during the follow-up period. We assessed the effects of original DCCT treatment-group assignment, mean glycated hemoglobin values, and frequency of hypoglycemic events on measures of cognitive ability, with adjustment for age at baseline, sex, years of education, length of follow-up, visual acuity, self-reported sensory loss due to peripheral neuropathy, and (to control for the effects of practice) the number of cognitive tests taken in the interval since the start of the DCCT. RESULTS: Forty percent of the cohort reported having had at least one hypoglycemic coma or seizure. Neither frequency of severe hypoglycemia nor previous treatment-group assignment was associated with decline in any cognitive domain. Higher glycated hemoglobin values were associated with moderate declines in motor speed (P=0.001) and psychomotor efficiency (P<0.001), but no other cognitive domain was affected. CONCLUSIONS: No evidence of substantial long-term declines in cognitive function was found in a large group of patients with type 1 diabetes who were carefully followed for an average of 18 years, despite relatively high rates of recurrent severe hypoglycemia. (ClinicalTrials.gov number, NCT00360893.) Copyright 2007 Massachusetts Medical Society.
RCT Entities:
BACKGROUND: Long-standing concern about the effects of type 1 diabetes on cognitive ability has increased with the use of therapies designed to bring glucose levels close to the nondiabetic range and the attendant increased risk of severe hypoglycemia. METHODS: A total of 1144 patients with type 1 diabetes enrolled in the Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study were examined on entry to the DCCT (at mean age 27 years) and a mean of 18 years later with the same comprehensive battery of cognitive tests. Glycated hemoglobin levels were measured and the frequency of severe hypoglycemic events leading to coma or seizures was recorded during the follow-up period. We assessed the effects of original DCCT treatment-group assignment, mean glycated hemoglobin values, and frequency of hypoglycemic events on measures of cognitive ability, with adjustment for age at baseline, sex, years of education, length of follow-up, visual acuity, self-reported sensory loss due to peripheral neuropathy, and (to control for the effects of practice) the number of cognitive tests taken in the interval since the start of the DCCT. RESULTS: Forty percent of the cohort reported having had at least one hypoglycemic coma or seizure. Neither frequency of severe hypoglycemia nor previous treatment-group assignment was associated with decline in any cognitive domain. Higher glycated hemoglobin values were associated with moderate declines in motor speed (P=0.001) and psychomotor efficiency (P<0.001), but no other cognitive domain was affected. CONCLUSIONS: No evidence of substantial long-term declines in cognitive function was found in a large group of patients with type 1 diabetes who were carefully followed for an average of 18 years, despite relatively high rates of recurrent severe hypoglycemia. (ClinicalTrials.gov number, NCT00360893.) Copyright 2007 Massachusetts Medical Society.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Augustina M A Brands; Geert Jan Biessels; Edward H F de Haan; L Jaap Kappelle; Roy P C Kessels Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112
Authors: Julie M Silverstein; Daniel Musikantow; Erwin C Puente; Dorit Daphna-Iken; Adam J Bree; Simon J Fisher Journal: Neurosci Lett Date: 2011-01-25 Impact factor: 3.046
Authors: Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Lenore J Launer; Michael E Miller; Jeff D Williamson; Ron M Lazar; Hertzel C Gerstein; Anne M Murray; Mark Sullivan; Karen R Horowitz; Jingzhong Ding; Santica Marcovina; Laura C Lovato; James Lovato; Karen L Margolis; Patrick O'Connor; Edward W Lipkin; Joy Hirsch; Laura Coker; Joseph Maldjian; Jeffrey L Sunshine; Charles Truwit; Christos Davatzikos; R Nick Bryan Journal: Lancet Neurol Date: 2011-09-28 Impact factor: 44.182
Authors: In Kyoon Lyoo; Sujung Yoon; Alan M Jacobson; Jaeuk Hwang; Gail Musen; Jieun E Kim; Donald C Simonson; Sujin Bae; Nicolas Bolo; Dajung J Kim; Katie Weinger; Junghyun H Lee; Christopher M Ryan; Perry F Renshaw Journal: Arch Gen Psychiatry Date: 2012-12